You also have to keep in mind that acquired resistance rates for immunotherapy are higher than efficacy. Acquired resistance is where patients initially responded to treatment, however, over time, their cancer has stopped responding.
Using the information from the summary table below:
- Average ORR = 34.4%
- Average Acquired Resistance = 38.6%
Bisantrene has been shown to sensitize an aggressive, resistant melanoma mouse model to anti-PD1 therapy. Given immunotherapy also has cardiotoxicity issues, Bisantrene sure does seem like an excellent candidate to pair with immunotherapy. This is further evidenced by patients who have received 7-8 grams of Bisantrene without cumulative toxicities. Pairing another drug with immunotherpy that also has cumulative toxicities is just a ticking time bomb. I think I am starting to really appreciate the role Bisantrene can play clinically - the ultimate sensitizing agent.
- Forums
- ASX - By Stock
- RAC
- Industry news
Industry news, page-2321
-
- There are more pages in this discussion • 85 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.59 |
Change
0.000(0.00%) |
Mkt cap ! $270.9M |
Open | High | Low | Value | Volume |
$1.59 | $1.62 | $1.57 | $180.6K | 113.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 145 | $1.57 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.60 | 23400 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 145 | 1.565 |
1 | 700 | 1.550 |
1 | 645 | 1.545 |
2 | 6750 | 1.540 |
1 | 134 | 1.535 |
Price($) | Vol. | No. |
---|---|---|
1.600 | 23400 | 1 |
1.620 | 10000 | 1 |
1.650 | 17029 | 2 |
1.690 | 6570 | 3 |
1.695 | 7731 | 1 |
Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online